Bluecrux has joined forces with biopharmaceutical company AstraZeneca to improve lab operations by implementing Binocs, Bluecrux’s lab planning technology, across 17 of AstraZeneca’s global quality control laboratories.
 
This strategic collaboration tackles the industry-wide challenge of seamlessly integrating quality control (QC) into supply chain (SC) operations to enhance operational efficiency and responsiveness.
 
AstraZeneca saw a significant opportunity for integration between quality control and its supply chain. When quality control labs—critical in ensuring the safety and efficacy of pharmaceutical products—operate in isolation from the supply chain, a longer response time is required to meet fluctuating demands, and ultimately, patient needs. Additionally, connecting QC and supply chain will result in direct and positive impact on lead times, inventory costs and regulatory compliance.
 
Enter Bluecrux’s technology Binocs, which integrates QC into the heart of supply chain operations, enabling precise capacity management and forecasting. By forecasting production needs and aligning them with QC capabilities, Binocs ensures that equipment and staff are optimally deployed, dramatically improving capacity utilization and accelerating product release cycles.
 
This collaboration aims to unlock significant hidden value, reducing lead times and inventory costs, consequently boosting AstraZeneca’s agility and competitiveness in the global market, which allows it to accelerate its delivery of medicines to patients around the globe.
 
Scott Barnard, Managing Director, Bluecrux US, says: “Through this collaboration, AstraZeneca has not only created deep and rich insights into their local and global network laboratory capacity, but they are transforming the culture and effectiveness of their planning processes by enabling collaborative and impactful discussions between QC and Supply Chain.”